BioCentury
ARTICLE | Financial News

Actelion maintains guidance, reports earnings

October 18, 2013 12:23 AM UTC

Actelion Ltd. (SIX:ATLN) said it is on track to meet its goal of double-digit core earnings growth in 2013. The company also still expects core earnings to be "at least at the same level" for 2014, with at least single-digit growth in 2015. The European biotech reported core EPS for the nine months ended Sept. 30 of CHF3.60, up 21% from CHF3.09 in the same period last year. Sales rose 4% to CHF1.3 billion ($1.5 billion), including a 3% increase in sales of pulmonary arterial hypertension (PAH) drug Tracleer bosentan to CHF1.14 billion ($1.3 billion). Percent changes are in local currencies. ...